Tomato-Soy Juice Cuts Inflammation by 20% in 4 Weeks

By VirentaNews Staff — May 26, 2026

A daily drink of tomato-soy juice rich in lycopene and soy isoflavones reduced levels of pro-inflammatory proteins in healthy adults with obesity after just four weeks, according to a peer-reviewed clinical trial led by researchers at The Ohio State University. The study, funded by the National Institutes of Health (NIH), found measurable declines in C-reactive protein (CRP) and interleukin-6 (IL-6)—key biomarkers linked to chronic inflammation and metabolic disease. This outcome matters because sustained low-grade inflammation in obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, suggesting that a simple dietary intervention could play a preventive role in public health.

Evidence from the Clinical Trial

The randomized, double-blind, placebo-controlled trial involved 50 adults with a body mass index (BMI) in the obesity range (30 or higher) who were otherwise healthy and not taking anti-inflammatory medications. Participants consumed either a specially formulated tomato-soy juice containing 30 mg of lycopene and 100 mg of soy isoflavones daily or a calorie-matched placebo drink for 28 days. Blood samples taken before and after the intervention showed that the treatment group experienced an average 18% reduction in high-sensitivity C-reactive protein (hs-CRP) and a 15% drop in IL-6, while the placebo group showed no significant changes. These results, published in the journal Nutrients, indicate that the bioactive compounds in the juice—particularly lycopene, a potent antioxidant found in tomatoes, and genistein, a soy isoflavone with known anti-inflammatory properties—may modulate immune signaling pathways. The study’s lead author, Dr. Mary Kilpatrick, emphasized that the effect size was clinically meaningful, especially given the short duration and lack of lifestyle changes among participants. These findings align with prior research from NIH-supported studies on dietary polyphenols and inflammation.

Key Researchers and Institutions

The study was conducted by a multidisciplinary team at The Ohio State University’s College of Education and Human Ecology, with expertise in nutritional biochemistry, chronic disease prevention, and clinical trial design. Principal investigator Dr. Kilpatrick has long studied plant-based interventions for metabolic health, while co-investigators include specialists in gastrointestinal immunology and nutrigenomics. The project received a $2.1 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, to expand the research into clinical populations with active inflammatory conditions. The next phase will test the tomato-soy juice in patients with chronic pancreatitis—a painful and hard-to-treat disease characterized by persistent pancreatic inflammation and elevated systemic markers like CRP. This patient group represents a higher-risk population where dietary modulation of inflammation could delay disease progression or reduce flare-ups, potentially lowering the need for opioids or surgical intervention.

Trade-Offs and Practical Considerations

While the anti-inflammatory benefits of the tomato-soy juice are promising, several trade-offs must be considered. First, the juice used in the study was specially formulated to ensure consistent dosing of lycopene and isoflavones—levels not typically found in commercial tomato or soy beverages. Regular grocery store versions may lack sufficient bioactive compounds to produce the same effect. Second, some individuals may be concerned about soy consumption due to outdated claims about hormonal effects, though current scientific consensus, as reviewed by the National Institutes of Health, confirms that moderate soy intake is safe and may even be protective against breast and prostate cancer. Third, while the juice is low in added sugars and calories, long-term adherence to daily consumption remains untested. Finally, while reducing inflammation is beneficial, it is not a substitute for weight loss, physical activity, or medical treatment in high-risk individuals. The intervention should be viewed as a complementary strategy, not a standalone solution.

Why the Timing Is Critical

The study arrives amid growing recognition that chronic inflammation is a root driver of many non-communicable diseases, particularly in the context of rising global obesity rates. With over 650 million adults classified as obese worldwide, according to the World Health Organization, scalable, low-cost interventions are urgently needed. At the same time, consumer interest in functional foods—beverages and foods designed to deliver health benefits beyond basic nutrition—has surged, creating a favorable environment for translating research into practice. The NIH’s decision to fund follow-up trials in pancreatitis reflects both the strength of the initial data and the unmet medical need in inflammatory gastrointestinal disorders. Moreover, the use of whole-food-based formulations, rather than isolated supplements, may improve bioavailability and patient adherence, a key factor in real-world effectiveness.

Where We Go From Here

In the next 6 to 12 months, researchers will launch a Phase II clinical trial involving 120 patients with chronic pancreatitis to assess whether the tomato-soy juice can reduce pain frequency, improve quality of life, and lower inflammatory biomarkers over 12 weeks. If successful, the intervention could be integrated into clinical nutrition guidelines for pancreatitis management. A second parallel study will explore the juice’s impact on gut microbiota composition, given emerging evidence that lycopene and isoflavones may promote beneficial bacteria linked to reduced inflammation. Meanwhile, food science teams are working with beverage manufacturers to develop commercially viable versions of the juice that maintain therapeutic compound levels without compromising taste or shelf life. Regulatory approval is not required for this food-based intervention, but rigorous labeling and quality control will be essential to avoid consumer confusion.

Bottom line — a simple, food-based intervention shows measurable anti-inflammatory effects in adults with obesity, offering a scalable, low-risk strategy to combat chronic disease, though its real-world impact will depend on formulation consistency, patient adherence, and validation in clinical populations.

Source: News